IL157830A0 - Imidazolidine derivatives, their preparation, and their use as antinflammatory agent - Google Patents

Imidazolidine derivatives, their preparation, and their use as antinflammatory agent

Info

Publication number
IL157830A0
IL157830A0 IL15783002A IL15783002A IL157830A0 IL 157830 A0 IL157830 A0 IL 157830A0 IL 15783002 A IL15783002 A IL 15783002A IL 15783002 A IL15783002 A IL 15783002A IL 157830 A0 IL157830 A0 IL 157830A0
Authority
IL
Israel
Prior art keywords
preparation
imidazolidine derivatives
antinflammatory agent
antinflammatory
agent
Prior art date
Application number
IL15783002A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL157830A0 publication Critical patent/IL157830A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
IL15783002A 2001-03-10 2002-02-23 Imidazolidine derivatives, their preparation, and their use as antinflammatory agent IL157830A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10111877A DE10111877A1 (de) 2001-03-10 2001-03-10 Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
PCT/EP2002/001917 WO2002072573A1 (en) 2001-03-10 2002-02-23 Imidazolidine derivatives, their preparation, and their use as antinflamatory agent.

Publications (1)

Publication Number Publication Date
IL157830A0 true IL157830A0 (en) 2004-03-28

Family

ID=7677184

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15783002A IL157830A0 (en) 2001-03-10 2002-02-23 Imidazolidine derivatives, their preparation, and their use as antinflammatory agent
IL157830A IL157830A (en) 2001-03-10 2003-09-09 History of imidazolidine, their preparation and medicinal products containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157830A IL157830A (en) 2001-03-10 2003-09-09 History of imidazolidine, their preparation and medicinal products containing them

Country Status (35)

Country Link
US (1) US6680333B2 (sh)
EP (1) EP1373249B1 (sh)
JP (1) JP4482277B2 (sh)
KR (1) KR100991678B1 (sh)
CN (1) CN1227248C (sh)
AR (1) AR035692A1 (sh)
AT (1) ATE293621T1 (sh)
AU (1) AU2002233358B2 (sh)
BG (1) BG108134A (sh)
BR (1) BR0207981A (sh)
CA (1) CA2440648C (sh)
CZ (1) CZ301893B6 (sh)
DE (2) DE10111877A1 (sh)
DK (1) DK1373249T3 (sh)
EE (1) EE05401B1 (sh)
ES (1) ES2240687T3 (sh)
HK (1) HK1062173A1 (sh)
HR (1) HRP20030713B1 (sh)
HU (1) HU228304B1 (sh)
IL (2) IL157830A0 (sh)
ME (1) MEP61108A (sh)
MX (1) MXPA03007634A (sh)
MY (1) MY129029A (sh)
NO (1) NO326001B1 (sh)
NZ (1) NZ528075A (sh)
PE (1) PE20020904A1 (sh)
PL (1) PL204622B1 (sh)
PT (1) PT1373249E (sh)
RS (1) RS51140B (sh)
RU (1) RU2303592C2 (sh)
SI (1) SI1373249T1 (sh)
SK (1) SK286652B6 (sh)
TW (1) TWI328587B (sh)
WO (1) WO2002072573A1 (sh)
ZA (1) ZA200306107B (sh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
CA2367969A1 (en) * 1999-03-22 2000-09-28 Ortho-Mcneil Pharmaceutical, Inc. Process of preparing 3s-3-amino-3-aryl propionic acid and derivatives thereof
WO2005034953A1 (ja) * 2003-10-10 2005-04-21 Kowa Co., Ltd. 血管新生抑制薬
EP2286224A4 (en) * 2008-05-05 2012-04-25 Univ Winthrop Hospital METHOD FOR IMPROVING THE CARDIOVASCULAR RISK PROFILE OF COX-INHIBITORS
US20130337470A1 (en) 2010-10-25 2013-12-19 Biogen Idec Ma Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
CN112707874A (zh) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 一种抗病毒化合物及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009506A1 (de) 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
DE4126277A1 (de) 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
CA2127462C (en) 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
AU674302B2 (en) 1992-02-12 1996-12-19 Biogen Idec Ma Inc. Treatment for inflammatory bowel disease
DE4207254A1 (de) 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4213634A1 (de) 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
EP0677060A1 (en) 1993-01-08 1995-10-18 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
JP3593343B2 (ja) 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
DE4308034A1 (de) 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
EP1759709B1 (en) 1994-01-25 2013-02-27 Elan Pharmaceuticals Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0767674A4 (en) 1994-06-29 1999-06-16 Texas Biotechnology Corp METHOD FOR INHIBITING THE BINDING OF INTEGRIN ALPHA 4 BETA 1 TO VCAM-1 OR FIBRONECTIN
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE19515177A1 (de) 1995-04-28 1996-10-31 Cassella Ag Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
EP0796855B1 (de) 1996-03-20 2002-02-06 Hoechst Aktiengesellschaft Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
NZ333904A (en) 1996-07-25 2000-06-23 Biogen Inc VLA-4 and IIb/IIIa cell adhesion inhibitors
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU748041B2 (en) 1997-10-31 2002-05-30 Aventis Pharma Limited Substituted anilides
GB9723789D0 (en) * 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
DE19751251A1 (de) * 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999054321A1 (en) 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
DE19821483A1 (de) * 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU758939B2 (en) * 1998-06-30 2003-04-03 Pfizer Products Inc. Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2000002903A1 (en) 1998-07-10 2000-01-20 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
DE19922462A1 (de) * 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
SK11262003A3 (sk) 2004-01-08
MY129029A (en) 2007-03-30
CN1496360A (zh) 2004-05-12
ES2240687T3 (es) 2005-10-16
IL157830A (en) 2009-05-04
AR035692A1 (es) 2004-06-23
HRP20030713A2 (en) 2005-02-28
EE05401B1 (et) 2011-04-15
EP1373249B1 (en) 2005-04-20
HUP0303455A2 (hu) 2004-03-01
YU70803A (sh) 2006-05-25
PL204622B1 (pl) 2010-01-29
BR0207981A (pt) 2004-06-15
WO2002072573A1 (en) 2002-09-19
NZ528075A (en) 2005-02-25
US6680333B2 (en) 2004-01-20
RU2303592C2 (ru) 2007-07-27
CA2440648A1 (en) 2002-09-19
RU2003129986A (ru) 2005-03-20
TWI328587B (en) 2010-08-11
HUP0303455A3 (en) 2005-06-28
DE10111877A1 (de) 2002-09-12
RS51140B (sr) 2010-10-31
PT1373249E (pt) 2005-07-29
CZ301893B6 (cs) 2010-07-21
CZ20032429A3 (cs) 2003-12-17
AU2002233358B2 (en) 2007-03-22
MXPA03007634A (es) 2003-12-04
PL362573A1 (en) 2004-11-02
EE200300436A (et) 2003-12-15
HK1062173A1 (en) 2004-10-21
CN1227248C (zh) 2005-11-16
HRP20030713B1 (en) 2006-02-28
DE60203791T2 (de) 2006-01-19
JP2004523574A (ja) 2004-08-05
BG108134A (bg) 2004-09-30
KR20030082980A (ko) 2003-10-23
EP1373249A1 (en) 2004-01-02
NO20033981L (no) 2003-09-09
DE60203791D1 (de) 2005-05-25
NO326001B1 (no) 2008-09-01
KR100991678B1 (ko) 2010-11-04
JP4482277B2 (ja) 2010-06-16
ATE293621T1 (de) 2005-05-15
MEP61108A (en) 2011-05-10
SI1373249T1 (sh) 2005-08-31
CA2440648C (en) 2010-06-15
HU228304B1 (en) 2013-03-28
DK1373249T3 (da) 2005-08-22
PE20020904A1 (es) 2002-12-10
US20030073723A1 (en) 2003-04-17
SK286652B6 (sk) 2009-03-05
NO20033981D0 (no) 2003-09-09
ZA200306107B (en) 2004-09-01

Similar Documents

Publication Publication Date Title
IL159275A0 (en) Phenylsulfonyl-1, 3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
HK1048999A1 (zh) 氮雜䓬吲衍生物，它們的製備和應用
HUP0401335A3 (en) Herbicidal pyridylpropynyloxyphenyl derivatives, preparation and use thereof
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
IL159507A0 (en) Substituted dihydro 3-halo-1h pyrazole-5-carboxylates, their preparation and use
HUP0500983A3 (en) Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate
MXPA03004644A (es) Derivados de fenilacetamdia-pirazol y su uso como agentes antitumorales.
HK1068336A1 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
AU2002359126A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU2002359123A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
HUP0105039A3 (en) Fungicidal propargylether derivatives, preparation and use thereof
HK1081954A1 (en) Novel 1,4-diazabicycloalkane derivatives, their preparation and use
TWI318974B (en) Acylaminothiazole derivatives, their preparation and their therapeutic use
IL135451A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
HUP0401092A3 (en) 5-halogen-6-phenyl-7-fluoralkylamino-triazolopyrimidines as fungicides, preparation and use thereof
HUP0600238A2 (en) Benzothiazole- and benzoxazole-4,7-dione derivatives and their use
IL157830A0 (en) Imidazolidine derivatives, their preparation, and their use as antinflammatory agent
PL365342A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
IL135452A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
HK1065792A1 (en) 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino Ä4,5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
IL159561A0 (en) Eurotinones and derivatives thereof, processes for preparing them, and their use
HUP0203455A3 (en) 2-arylquinoline derivatives, preparation and therautic use thereof
AU7660601A (en) Pseudo-metalloproteins, their preparation and use
HK1063793A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
IL141804A0 (en) Benzotriazole-1-yl-uronium derivatives, process for their preparation and use thereof